IRIS
PETRONINI, Pier Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.095
AS - Asia 10.305
EU - Europa 7.907
SA - Sud America 1.413
AF - Africa 521
Continente sconosciuto - Info sul continente non disponibili 339
OC - Oceania 12
Totale 34.592
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.700
SG - Singapore 3.584
CN - Cina 2.940
IT - Italia 1.738
VN - Vietnam 1.597
FI - Finlandia 1.151
IE - Irlanda 1.139
BR - Brasile 1.091
SE - Svezia 1.016
DE - Germania 805
HK - Hong Kong 712
UA - Ucraina 547
FR - Francia 362
ZA - Sudafrica 328
NL - Olanda 301
BD - Bangladesh 300
TR - Turchia 297
CA - Canada 232
GB - Regno Unito 231
IN - India 210
RU - Federazione Russa 164
AR - Argentina 116
AT - Austria 98
BE - Belgio 88
KR - Corea 78
CI - Costa d'Avorio 73
MX - Messico 72
JP - Giappone 71
PL - Polonia 61
CO - Colombia 60
IQ - Iraq 59
ID - Indonesia 58
EC - Ecuador 55
PK - Pakistan 46
ES - Italia 45
PH - Filippine 44
VE - Venezuela 40
CZ - Repubblica Ceca 38
TH - Thailandia 37
SA - Arabia Saudita 26
IR - Iran 24
LT - Lituania 24
MA - Marocco 24
UZ - Uzbekistan 24
EG - Egitto 22
JO - Giordania 22
JM - Giamaica 19
KE - Kenya 18
MY - Malesia 17
EE - Estonia 16
TN - Tunisia 16
TW - Taiwan 16
CR - Costa Rica 15
PS - Palestinian Territory 15
AE - Emirati Arabi Uniti 14
IL - Israele 14
GT - Guatemala 12
KZ - Kazakistan 12
PY - Paraguay 12
AZ - Azerbaigian 11
AL - Albania 10
CL - Cile 10
LB - Libano 10
NP - Nepal 10
PE - Perù 10
RO - Romania 10
UY - Uruguay 10
DZ - Algeria 9
HU - Ungheria 9
OM - Oman 9
AU - Australia 8
BO - Bolivia 8
HN - Honduras 8
MD - Moldavia 8
QA - Qatar 8
ET - Etiopia 7
LU - Lussemburgo 7
SY - Repubblica araba siriana 7
CH - Svizzera 6
GE - Georgia 6
KG - Kirghizistan 6
NI - Nicaragua 6
PA - Panama 5
PT - Portogallo 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
DO - Repubblica Dominicana 4
GP - Guadalupe 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
AM - Armenia 3
BG - Bulgaria 3
BH - Bahrain 3
BW - Botswana 3
EU - Europa 3
HR - Croazia 3
LK - Sri Lanka 3
LY - Libia 3
NO - Norvegia 3
SC - Seychelles 3
Totale 34.205
Salva come PNG Salva come JPEG
Città #
Singapore 1.846
Ashburn 1.540
San Jose 1.241
Dublin 1.134
Chandler 1.092
Dallas 1.030
Santa Clara 875
Beijing 674
Hong Kong 662
Jacksonville 617
Ann Arbor 597
Parma 499
Ho Chi Minh City 475
Council Bluffs 463
Dearborn 447
Boardman 372
Hanoi 359
New York 331
Johannesburg 313
Los Angeles 290
Nanjing 264
Izmir 244
Shanghai 235
Princeton 210
Munich 208
Lauterbourg 207
San Mateo 178
Hefei 166
Wilmington 140
Milan 131
Bremen 128
Chicago 128
Helsinki 115
Buffalo 108
São Paulo 108
Toronto 103
Nanchang 98
Kunming 93
Shenyang 92
Hebei 85
Moscow 84
Vienna 84
Jinan 82
Bologna 76
Haiphong 76
Abidjan 73
Woodbridge 72
Brussels 71
Rome 69
Tianjin 66
Frankfurt am Main 64
Da Nang 63
Columbus 61
Des Moines 59
Houston 58
Seattle 57
Modena 53
Seoul 53
Guangzhou 52
Tokyo 52
Marseille 50
Changsha 49
Turku 49
The Dalles 48
Jiaxing 46
Phoenix 46
Brooklyn 43
London 43
Warsaw 42
Pune 40
Rio de Janeiro 39
Montreal 37
Amsterdam 36
Denver 35
Norwalk 35
Washington 34
Düsseldorf 33
Stockholm 33
Jakarta 32
Reggio Emilia 32
San Francisco 31
Brasília 28
North Bergen 28
Orem 28
Belo Horizonte 27
Boston 27
Hangzhou 26
Manchester 26
Redmond 25
Atlanta 24
Biên Hòa 24
Charlotte 24
Augusta 23
Bogotá 23
Chennai 23
Dhaka 23
Fremont 23
Tashkent 23
Zhengzhou 23
Hải Dương 22
Totale 20.526
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 370
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 319
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 297
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 270
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 269
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 264
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 257
Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model 248
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 238
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 233
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 229
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 225
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 224
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 224
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 224
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 223
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 223
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 222
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 219
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 215
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 213
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 210
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 210
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 209
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 207
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 206
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 203
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 202
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 202
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 199
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 197
Characterization of gefitinib uptake in NSCLC cell lines 197
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 197
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 197
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 196
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 193
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 192
5-benzylidene-hydantoins as new inhibitors of cell proliferation 190
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 190
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 189
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 189
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 188
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 187
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 186
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 185
Left lung allotransplantation in the rabbit. An experimental model for assessment of lung preservation 185
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 184
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 184
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 183
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 182
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 181
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 180
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 179
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 179
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 178
Interaction between occupational radon exposure and tobacco smoke: a systematic review 175
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 175
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 174
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 173
An original application of plasma expanders: heart-lung preservation. 173
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 173
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 173
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 171
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 170
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 169
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 168
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 167
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 166
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 165
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 165
Adaptive cellular response to osmotic stress in pig articular chondrocytes 165
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 164
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 164
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 163
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 163
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 163
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 160
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 160
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 160
Synergistic activity of letrozole and sorafenib on breast cancer cells 158
Mannich base derivatives as novel EGFR irreversible inhibitors 157
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 156
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 156
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 156
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 155
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 155
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 155
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 154
SiO2/SiC core-shell nanowires for nanomedicine applications 154
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 153
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 153
New MDR1 inhibitors for overcoming multidrug resistance 153
Alterazioni della degradazione proteasoma-dipendente nel corso dell’invecchiamento ed effetti delle restrizioni caloriche 152
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 152
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 151
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 151
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 151
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 151
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 151
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 151
Totale 18.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.735
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.735
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022862 0 0 0 0 26 12 141 131 62 76 74 340
2022/20234.288 422 456 285 283 433 470 39 274 1.376 28 170 52
2023/20241.849 88 141 59 50 151 456 135 144 65 96 160 304
2024/20255.776 190 299 369 407 558 621 313 236 784 502 511 986
2025/202612.267 1.114 1.165 1.537 1.116 1.621 664 1.306 378 1.663 916 476 311
2026/20272.454 368 653 678 729 26 0 0 0 0 0 0 0
Totale 34.592